Skip to content

Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP)

Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP) - a Randomized Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04472468
Acronym
PMAP
Enrollment
50
Registered
2020-07-15
Start date
2020-01-01
Completion date
2024-09-30
Last updated
2024-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pericardial Effusion Malignant

Keywords

pericardial effusion, malignancy, pericardiotomy.

Brief summary

Pericardial effusion is a common complication in patients with metastatic malignancy. While pericardiocentesis provide effective relieve from life-threatening situation such as cardiac tamponade, recurrence of pericardial effusion after pericardiocentesis is common. We hypothesize that percutaneous balloon pericardiotomy in addition to standard pericardiocentesis with prolonged drainage can prevent pericardial effusion recurrence in patients with malignant pericardial effusion.

Detailed description

Pericardial effusion is a common complication in patients with metastatic malignancy with an incidence as high as 21%. The occurrence of malignant pericardial effusion significantly impacts on patient's survival and quality of life. While pericardiocentesis provide effective relieve from life-threatening situation such as cardiac tamponade, recurrence of pericardial effusion after pericardiocentesis is common and occurs in as high as 31% of patients. Retrospective data has shown that prolonged pericardial drainage might reduce the recurrence rate but at the cost of increased risk of infection and prolonged hospital stay. Surgical pericardiotomy was used in the past but was not shown to reduce recurrence over prolonged pericardial drainage and is associated with a higher rate of complications. Surgical pericardial window creation via a mini-thoracotomy might be an effective treatment and can be considered in patient with pericardial tamponade. The safety and feasibility of Percutaneous Balloon pericardiotomy (PBP) has been first described 1993 and has been shown to be an alternative treatment for patient with malignant pericardial effusion. However, no data is available on the efficacy of PBP in reducing the recurrence of pericardial effusion, in comparison with standard pericardiocentesis with prolonged drainage. We aim to perform a single centre, randomized, prospective, open label controlled pragmatic trial to compare percutaneous balloon pericardiotomy (treatment) to standard pericardiocentesis with prolonged drainage (control) in preventing pericardial effusion recurrence in patients with malignant pericardial effusion.

Interventions

DEVICEPercutaneous Balloon Pericardiotomy

* Subxiphoid approach under fluoroscopic guidance is used. * An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space. * Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

multi-center, randomized, prospective, open label controlled pragmatic trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with confirmed active malignancy AND, * Presence of at least moderate (\>10cm) pericardial effusion on CT or Echocardiography

Exclusion criteria

* Patients unable to give an informed consent, * Previous history of open-heart surgery * Previous history of pericardial window or pericardial instillation of sclerosing therapy. * Scheduled thoracic or cardiac surgery within the next 3 months * Patients with contraindications for endovascular procedure such as disseminated intravascular coagulopathy or significant ongoing bleeding tendency, and systemic septicaemia. * Patient with small or loculated pericardial effusion that is not accessible by subxiphoid approach.

Design outcomes

Primary

MeasureTime frameDescription
Pericardial effusion recurrence3 monthsRecurrence of pericardial effusion after index procedure, defined as development of moderate or more pericardial effusion (\>10mm) on follow-up imaging.
Procedural related complicationsImmediate after interventionProcedural related complications including procedural related death, need for urgent surgical intervention, pleural effusion and pneumothorax

Secondary

MeasureTime frameDescription
cardiac tamponade3 monthsOccurrence of cardiac tamponade as defined by echocardiographic finding of any of the following: 1. diastolic collapse of the right atrium, 2. Diastolic collapse of the right ventricle, 3. respiratory variation of the mitral E' velocity \> 25% or tricuspid E' velocity \>40%, 4. dilated IVC \>20mm and \<50% respiratory reduction.
Quality of life measure (using Functional Assessment of Cancer Therapy - General version (Chinese version)).3 months27 items self-administered questionnaire examining the impact of a cancer related therapy on 4 domains of life using a 5-points scale.
Survival3 monthsoverall survival
Catheter tract tumor seeding3 monthsEvidence of tumour seeding in catheter tract or extra-pericardial cavity
Ascites/Pleural effusion3 monthsOccurrence of ascites and pleural effusion by either clinical examination or on radiological investigation.
Pericardial drain indwelling timeduring index procedurePericardial drain indwelling time at index procedure
Pericardial effusion free survival3 monthssurvival without recurrence of pericardial effusion

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026